(Q34604314)

English

Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

schizoaffective disorder

1 reference

based on heuristic

inferred from title

author name string

K P Grootens

1

1 reference

Europe PubMed Central

3 August 2017

N M J van Veelen

2

1 reference

Europe PubMed Central

3 August 2017

J Peuskens

3

1 reference

Europe PubMed Central

3 August 2017

B G C Sabbe

4

1 reference

Europe PubMed Central

3 August 2017

E Thys

5

1 reference

Europe PubMed Central

3 August 2017

J K Buitelaar

6

1 reference

Europe PubMed Central

3 August 2017

R J Verkes

7

1 reference

Europe PubMed Central

3 August 2017

R S Kahn

8

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

19 June 2009

1 reference

Europe PubMed Central

3 August 2017

Schizophrenia Bulletin

1 reference

Europe PubMed Central

3 August 2017

37

1 reference

Europe PubMed Central

3 August 2017

2

1 reference

Europe PubMed Central

3 August 2017

352-361

1 reference

Europe PubMed Central

3 August 2017

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Metabolic considerations in the use of antipsychotic medications: a review of recent evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

Schizophrenia and increased risks of cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Pharmacological treatments for first-episode schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Olanzapine for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Remission in schizophrenia: proposed criteria and rationale for consensus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

New generation antipsychotics for first episode schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Ziprasidone for schizophrenia and severe mental illness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

A rating scale for drug-induced akathisia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

7 July 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

Ziprasidone-associated depressive state in schizophrenic patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3044623

26 October 2018

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19542525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19542525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing depression in schizophrenia: the Calgary Depression Scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/19542525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/SCHBUL/SBP037

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34604314&oldid=1510086539"